Retatrutide weight loss claims: what 34 lbs in 4 weeks actually means

What did @reagos_fitness actually say?

The creator reported dropping from 257.6 to 223.4 pounds over four weeks while taking what they call "red up" at 4 milligrams. They also mentioned starting "tessa" (likely tesofensine) about a week and a half in. The headline claim is simple: "zero side effects whatsoever" and roughly 34 pounds lost in a month. That's the claim worth examining.

They're not pretending this is a clinical setting. It's a personal update, filmed casually, with no mention of medical supervision, bloodwork, or dietary details. That context matters when you try to evaluate anything they're saying.

Does the science back this up?

The weight loss figure is plausible but sits at the aggressive end of what published data suggests. Retatrutide is a triple agonist targeting GIP, GLP-1, and glucagon receptors. In the Phase 2 trial published by Jastreboff et al. (2023, NEJM), participants on higher doses lost up to 24% of body weight over 48 weeks, which averages out to roughly 2-3 pounds per week in the most responsive group.

Losing 34 pounds in four weeks would require a sustained caloric deficit far beyond what most people achieve, even with aggressive pharmacological appetite suppression. Early weeks often include water weight, glycogen depletion, and reduced gut content, all of which can inflate short-term numbers significantly. The creator's claim of "a little over three pounds" in the most recent week is actually more consistent with what the literature describes for ongoing fat loss.

• Jastreboff et al., 2023 (NEJM): Phase 2 retatrutide trial showing dose-dependent weight reduction
• Early rapid loss is likely partly non-fat mass, not pure adipose reduction

What did they get wrong (or right)?

The "zero side effects" claim is where the video gets shaky. It's not that the creator is lying about their personal experience. It's that presenting zero sides as a baseline expectation for retatrutide is misleading to anyone watching. The Jastreboff 2023 trial reported nausea in over 40% of participants at higher doses, along with vomiting, diarrhea, and injection site reactions. Some people genuinely tolerate GLP-1 class drugs better than others, but framing zero sides as the norm is not accurate.

What they got right: staying at 4mg without escalating is actually a reasonable approach if tolerability is good. Dose-dependent side effects in the trial increased with higher doses, so not chasing higher milligrams is sensible self-reported behavior, whatever the supervision situation looks like.

The mention of stacking with tesofensine is worth flagging. Tesofensine is a triple monoamine reuptake inhibitor studied for obesity but not approved anywhere. Combining it with a potent appetite suppressant like retatrutide has no published safety data, and the cardiovascular risk profile of tesofensine alone includes elevated heart rate and blood pressure.

What should you actually know?

Retatrutide is not approved by the FDA as of this writing. It is in Phase 3 trials. Anyone using it is accessing a compound outside of a regulated approval pathway, which means purity, dosing accuracy, and sterility are not guaranteed through any standard process. That's not a moral judgment. It's a practical risk that the video does not mention.

The weight loss numbers in this video, while striking, are not a reliable guide to what someone else would experience. Body composition, starting weight, diet, activity, and individual receptor sensitivity all vary significantly. A 257-pound person losing weight rapidly in week one is not the same physiological story as someone lighter doing the same thing.

If you're seeing videos like this and considering a similar path, the conversation starts with a licensed provider who can review your metabolic panel, cardiovascular history, and current medications. The 34-pound figure is real to this person. It is not a promise.